Synchron Raises $200M to Accelerate Brain-Computer Interface Launch
Synchron secured $200 million to speed up pivotal trials and prepare for the commercial release of its Stentrode brain-computer interface (BCI) system.
Differences in Brain-Computer Interface Approaches
BCI companies develop devices that capture and interpret brain signals to trigger actions like hands-free control of digital devices. However, their methods vary significantly.
- Elon Musk’s Neuralink requires implanting a device by removing a portion of the skull.
- Synchron’s first-generation product is implanted via a less invasive catheter procedure.
Each approach balances procedure invasiveness against the signal quality the device can capture.
Device Specifications and Capabilities
- Synchron’s Stentrode device includes 16 electrodes.
- Neuralink’s N1 Implant has 1,024 electrodes.
Despite fewer electrodes, the Stentrode enables severely paralyzed users to control personal devices effectively.
Funding Goals and Future Plans
The new Series D funding allows Synchron to leverage the strengths of its first-generation device while addressing its limitations over time.
Funds will be allocated to:
- Accelerate pivotal clinical trials.
- Prepare for commercial launch of the Stentrode BCI system.
- Develop a next-generation transcatheter high-channel whole-brain interface.
Integration of Artificial Intelligence
Synchron is expanding its AI team based in New York City to develop models that learn from brain data, aiming to decode thoughts in real time.
Synchron’s goal is to decode thought in real time.
Summary: Synchron’s $200M funding accelerates clinical trials and commercial launch of its minimally invasive brain-computer interface, while advancing AI-driven real-time thought decoding.